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Joshua A. Beckman, MD, Mark A. Creager, MDSEE PAGE 1444P eripheral artery disease (PAD) affects 7 to 8million persons living in the United Statesand over 200 million persons worldwide
(1,2). In approximately 2% to 3% of patients with
PAD, arterial perfusion is inadequate to sustain basal
metabolic requirements, resulting in critical limb
ischemia (CLI), typically affecting the most distal seg-
ments of the leg and manifested as rest pain, skin ul-
ceration, and/or frank gangrene.
Patients with CLI are at risk for 2 important
sequelae: ﬁrst, the severity of leg blood-ﬂow reduc-
tion forebodes a high rate of amputation in the
absence of revascularization (3). Second, the presence
of CLI is indicative of a large systemic atherosclerotic
burden, which increases the likelihood of adverse
cardiovascular events, including myocardial infarc-
tion, stroke, and death. Thus, 2 competing consider-
ations must weigh in the analysis when balancing the
potential beneﬁts of revascularization: the expected
limb salvage versus the expected cardiovascular
outcome of the patient. It is at this nexus of palliation
and survival that CLI sits and represents a good
example of health care in the present day: In the
setting of competing risks, when is the risk of a
palliative procedure of value?
The discussion regarding which patients with CLI
would beneﬁt from revascularization becomes even
more compellingwhen taking into account the aging of
the population that signiﬁcantly increases the number
of elderly patients at high mortality risk, both from
complications of limb-saving procedures, adverse
cardiovascular events, and other noncardiovascular*Editorials published in JACC: Cardiovascular Interventions reﬂect the
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risk of revascularization has diminished, lowering the
threshold to consider surgery or percutaneous pro-
cedures. For example, in the PREVENT III (Prevention
of Infrainguinal Vein Graft Failure III) study of a novel
molecular therapy to reduce vein graft failure in 1,404
patients, 30-day mortality was <3% (4). Similar ob-
servations were made in the BASIL (Bypass versus
Angioplasty in Severe Ischaemia of the Leg) trial (5) and
National Surgical Quality Improvement Program data
(6). Yet, over the last 15 years, intermediate-term sur-
vival, deﬁned as 1- to 2-yearmortality, has not changed
appreciably. In 1997, the I.C.A.I. Group (Gruppo di
Studio dell’Ischemia Cronica Critica degli Arti Inferi-
ori) reported a 31% 2-year mortality in patients with
CLI. Two-year mortality in the BASIL trial was 26.8%
(7). In the Swedish national experience, the mortality
rate was 27.7 and 13.4 per hundred person-years for
those with and without diabetes, respectively (8).
Thus, the difﬁculty in determining who will beneﬁt
from a surgical or endovascular procedure rests less on
the procedural morbidity and mortality than on the
expectation of survival long enough to accomplish
recovery and enjoy its effects.It is in this aspect that Soga et al. (9), in this issue of
JACC: Cardiovascular Interventions, have improved
the process of patient selection. The authors retro-
spectively evaluated 995 patients who were followed
for more than 2 years after endovascular revascular-
ization for CLI. The mortality rate, as expected, was
high at 41%, and cardiovascular death was the most
common cause of death. Using this cohort, the au-
thors determined the demographic and medical fac-
tors that associated most strongly with 2-year
mortality and devised a scoring system to estimate
survival at 2 years. Patients with 8 points, for
example with Rutherford class 5 disease, age 81 years,
who cannot walk, and whose left ventricular ejection
TABLE 1 Intermediate-Term Risk Prediction Models
Soga et al. (9) Points FINNVASC Points PREVENT III Points BASIL
Variables Nonambulatory status 2 Diabetes mellitus 1 Dialysis 4 Tissue loss
Rutherford class 1.5–3.0 Gangrene 1 Tissue loss 3 Body mass index
Cerebrovascular disease 1 Coronary artery disease 1 Age >75 yrs 2 Creatinine
Hemodialysis 2 Urgent operation 1 Coronary artery disease 1 Bollinger score
Body mass index 1.0–2.0 Age
Age 1.5–3.0 Smoking
Left ventricular
ejection fraction
2 Coronary artery disease
Ankle pressure
Method of
use
Total score indicates risk Total score indicates risk Risk categories divided
at 3 and 8 points
Model available
for download
Adapted from Moxey et al. (7) with addition of the Soga et al. data (9).
BASIL ¼ Bypass versus Angioplasty in Severe Ischaemia of the Leg; FINNVASC ¼ Finland National Vascular registry; PREVENT III ¼ Prevention of Infrainguinal Vein Graft
Failure III.
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1451fraction is 40% to 49%, have a 50% 2-year survival rate.
Awareness of the likelihood of intermediate-term
survival better informs the discussion with patients
about the beneﬁts of a procedure, its attendant risks,
and the patient’s intermediate-term outcomes.
There have been other published risk assessment
tools for patients with severe PAD who are under
consideration for revascularization (Table 1). Most of
the studies supporting these tools have focused on
factors similar to Soga et al. (8–14). Moxey et al. (7)
compared the BASIL survival prediction model to
the FINNVASC (Finland National Vascular) registry
and the PREVENT models. In this study, the ability of
each model to predict mortality is performed by
comparing the area under the curve (AUC) for each
receiver-operating characteristic curve. The AUCs for
2-year mortality derived from these studies ranged
from 0.533 to 0.664, which are considered poor to
good for a prediction model. Soga et al. (9) did not
report an AUC for their receiver-operating character-
istic curve. As can be seen in the table, many of the
factors in each model are similar to each other and
rely heavily on demographic and medical factors.
Combining these datasets to generate a most accurate
survival model would be helpful for physicians and
surgeons who care for these patients.
Still, demographic and medical factors do not
provide the whole story, and other factors must betaken into consideration when pondering the beneﬁts
of revascularization for CLI. For example, although
the primary purpose of revascularization in patients
with CLI is limb salvage, an important extended goal
is the restoration of ambulation. Other important
factors, such as nursing home residence, inability to
leave the home, and dementia, are potent predictors
of an inability to ambulate after revascularization, and
should also be incorporated into the decision-making
analysis (15,16). Thus, we believe appropriate decision
making requires, not only an understanding of the
periprocedural and intermediate-term risks for car-
diovascular events, including death, and the likeli-
hood of limb salvage, but also the impact of the
procedure on sustained functional recovery, inde-
pendence, and quality of life.
Soga et al. (9) have provided new information
to assist in understanding intermediate-term out-
comes. The challenge will be to study populations
large enough to integrate patient characteristics
and comorbidities with all of these outcomes together
to improve clinical decision making in patients with
CLI.
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